Psivant Therapeutics
Psivant Therapeutics develops small-molecule drugs to convert biologically validated but hard-to-drug protein targets into oral therapies. The company uses its QUAISAR platform, combining molecular simulation, quantum mechanics, and artificial intelligence with biophysics and mechanistic biology to identify and optimize allosteric inhibitors. Its focus is on immunology and inflammation, particularly targets in the TNF superfamily that have been dominated by injectable biologics. Psivant operates as a biotechnology company serving pharmaceutical and biotech partners to advance preclinical small-molecule candidates.
Psivant Therapeutics
Psivant Therapeutics develops small-molecule drugs to convert biologically validated but hard-to-drug protein targets into oral therapies. The company uses its QUAISAR platform, combining molecular simulation, quantum mechanics, and artificial intelligence with biophysics and mechanistic biology to identify and optimize allosteric inhibitors. Its focus is on immunology and inflammation, particularly targets in the TNF superfamily that have been dominated by injectable biologics. Psivant operates as a biotechnology company serving pharmaceutical and biotech partners to advance preclinical small-molecule candidates.